Generating candidates is the solved part.
Deciding what to build and what to kill is the harder problem.
Biodesign Academy studies decision-making in AI-driven biology. What evidence actually matters before a team commits. Where model confidence misleads. How organisations act on incomplete, probabilistic outputs when the cost of getting it wrong is a wasted experimental cycle or a failed platform claim.
THE PROBLEM
AI systems now produce biological outputs faster than organisations can evaluate them.
The gap between what models generate and what teams can act on is where poor decisions happen. Outputs that look credible but carry hidden risk. Confidence scores that hold up at the global level and break down locally. Decisions to proceed made on thin evidence because the pressure to move was stronger than the case for pausing.
That gap is what this project studies.
RESEARCH
Three tracks. One question.
How should teams act on AI-generated biological outputs under real constraints?
Decision Intelligence
The core track. Studies what it actually takes to justify a decision to proceed — not just whether an output looks plausible, but whether the evidence behind it is strong enough to warrant the commitment. Failure mode analysis, evidence hierarchies, and the question of when uncertainty should stop progress rather than accelerate it.
Trust and Evidence
What kinds of outputs warrant confidence, and where is that confidence assumed without justification? This track looks at what evidence should move the needle, and where teams build or break trust in AI-generated biology without realising it.
Biosecurity and Misuse Stress-Testing
Where do decision processes become too permissive? This track stress-tests AI-biology workflows for the failure modes that standard validation misses, and the blind spots between platform optimism and genuine risk.
CURRENT WORK
Pre-Synthesis Readiness Benchmark
An ongoing empirical study of what separates AI-generated protein candidates that are genuinely synthesis-ready from those that merely appear plausible under standard model scoring. The benchmark is building out a failure-mode taxonomy, risk-scoring criteria, and a practical decision framework for candidate evaluation before wet-lab commitment.
COMMERCIAL ARM
BuildGate.bio by Biodesign Academy
Buildgate is the B2B arm of Biodesign Academy. It applies the decision-intelligence framework to real candidate pipelines: pre-synthesis review, risk-scoring, and structured go/no-go criteria for AI-native biotech teams before they commit experimental spend.
BuildGate.bio
Research updates, framework notes, and decision-intelligence analysis for AI-native biotech teams. No hype. No sponsored content. Published when there is something worth saying.
Published by Biodesign Academy. Unsubscribe at any time.
